Efficacy and safety of the platelet-activating factor receptor antagonist BN 52021 (Ginkgolide B) in patients with severe sepsis: A randomised, double-blind, placebo-controlled, multicentre trial

Clinical Drug Investigation

Volumn 24, Issue 3, 2004, Pages 137-147

  Albrecht, D M ^a   Van Ackern, K ^b   Bender, H J ^b   Hof, H ^b   Kox, W ^c   Victor, N ^d   Funk, P ^e   Kieser, M ^e   Kohler S ^e   Krausch, D ^c   Marzi, I ^f   Menges, T ^g   Schmidt, H ^h  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GINKGOLIDE B; PLACEBO;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; SURGICAL PATIENT; TREATMENT OUTCOME;

EID: 11144356908     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424030-00002     Document Type: Article

References (32)

1. Dhainaut JF, Hamy I, Schremmer B. Manipulation of the immunoinflammatory cascade in sepsis: facts and perspectives. In: Vincent JL, editors. Update in intensive care and emergency medicine. Berlin: Springer, 1990: 100-8
2. Inarrea P, Gomez-Cambronero J, Pascual J, et al. Synthesis of PAF-acether and blood volume changes in gram-negative sepsis. Immunopharmacology 1985; 9: 45-52
3. Bussolino F, Porcellini MG, Varese L, et al. Intravascular release of platelet activating factor in children with sepsis. Thromb Res 1987; 48: 619-20
4. Lopez Diez F, Nieto ML, Fernandez-Gallardo S, et al. Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 1989; 83: 1733-40
5. Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res 2000; 39: 41-82
6. Ayala A, Chaudry ICH. Platelet activating factor and its role in trauma, shock, and sepsis. New Horiz 1996; 4 (2): 265-75
7. Braquet P, Touqui L, Shen TY, et al. Perspectives in platelet-activating factor research. Pharmacol Rev 1987; 39: 97-145
8. Graham RM, Stephens CJ, Silvester W, et al. Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med 1994; 22: 204-12
9. Dhainaut JF, Tenaillon A, LeTulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994; 22 (11): 1720-8
10. Dhainaut JF, Tenaillon A, Hemmer M, et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1998; 26 (12): 1963-71
11. Mózes T, Heiligers JPC, Tak CJAM, et al. Platelet activating factor is one of the mediators involved in endotoxic shock in pigs. J Lipid Mediat 1991; 4: 309-26
12. Mózes T, Zijlstra FJ, Heiligers JPC. Interactions between platelet activating factor and eicosanoids during endotoxic shock in anaesthetized pigs. Mediat Inflam 1992; 1: 183-90
13. Moore JM, Earnest MA, DiSimone AG, et al. A PAF receptor antagonist, BN 52021, attenuates thromboxane release and improves survival in lethal canine endotoxemia. Circ Shock 1991; 35: 53-9
14. Fletcher JR, DiSimone AG, Earnest MA. Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. Ann Surg 1990; 211: 312-6
15. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29
16. Le Gall J-R, Loirat P, Alperovitch A, et al. A simplified acute physiology score for ICU patients. Crit Care Med 1984; 12: 975-7
17. Rowan KM, Kerr JH, Major E, et al. Intensive Care Society's APACHE II study in Britain and Ireland - I: variations in case mix of adult admissions to general intensive care units and impact on outcome. BMJ 1993; 307: 972-7
18. Murray JT, Matthay MA, Luce JM, et al. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138: 720-3
19. Kieser M, König J, Victor N. Biometrische Planung von klinischen Prüfungen, bei denen eine überlegene Wirksamkeit nur in einer Subgruppe zu erwarten ist. In: Kunath H, Lochmann U, Straube R, et al., editors. Medizin und Information. München: MMV, 1994: 434-7
20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56
21. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990; 9: 1447-54
22. Froon AMF, Greve JWM, Buurman WA, et al. Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial. Shock 1996; 5: 313-9
23. Poeze M, Froon AHM, Ramsay G, et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized, phase II trial. Shock 2000; 14: 421-8
24. Macfarlane JT, Colville A, Guion A, et al. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993; 341: 511-4
25. Vincent J-L, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European prevalence of infection in intensive care (EPIC) study. JAMA 1995; 274: 639-44
26. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340: 207-14
27. Witthaut R, Werdan K. Ergebnisforschung am Beispiel der Sepsis. Internist 1996; 37: 1249-59
28. Fink MP. Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis. J Antimicrob Chemother 1998; 41 Suppl. A: 81-94
29. Mira J-P, Cariou A, Grall F, et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. JAMA 1999; 282: 561-8
30. Hermans PWM, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 1999; 354: 556-60
31. Westendorp RGJ, Hottenga J-J, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354: 561-3
32. Menges T, Hermans PWM, Böning O, et al. Genotypisierung polytraumatisierter Patienten. Untersuchungen zum Plasminogenaktivator- Inhibitor (PAI-1)-Promotor-Genpolymorphismus [abstract]. Anaesthesist 1998; 47: 865-6